Antibodies

16 Oct 2017 Takeda Presents Updated Results from Pivotal Phase 2 ALTA Trial of ALUNBRIGTM (brigatinib) in ALK-Positive Non-Small Cell Lung Cancer
16 Oct 2017 Opdivo Alone or Combined with Yervoy Shows Encouraging Response and Survival Rates in Recurrent Small Cell Lung Cancer Patients with High Tumor Mutation Burden, in Exploratory Analysis from Phase 1/2 Study CheckMate -032
14 Oct 2017 Janssen Announces U.S. FDA Approval Of STELARA® (ustekinumab) For The Treatment Of Adolescents With Moderate To Severe Plaque Psoriasis
12 Oct 2017 Philogen Announces Authorization from FDA of a Pivotal Registration Trial in USA for the Treatment of Resectable Melanoma
11 Oct 2017 Seattle Genetics Announces Additional Clinical Collaborations to Evaluate SGN-LIV1A in Triple Negative Breast Cancer
11 Oct 2017 MabVax Therapeutics Initiates Patient Enrollment in a Phase 1 Trial for MVT-1075, a New Radioimmunotherapy Treatment for Advanced Pancreatic, Colon and Lung Cancers
11 Oct 2017 Ultragenyx and Kyowa Hakko Kirin Announce FDA Acceptance and Priority Review Designation of Burosumab’s Biologics License Application
10 Oct 2017 OncoSec Initiates Registration Directed Clinical Trial, KEYNOTE-695, of ImmunoPulse® IL-12 in Combination with Merck's KEYTRUDA® (pembrolizumab)
10 Oct 2017 Genmab and Seattle Genetics to Initiate New Study of Novel Antibody-Drug Conjugate Tisotumab Vedotin in Cervical Cancer
10 Oct 2017 Seattle Genetics and Astellas Initiate Pivotal Trial of Enfortumab Vedotin for Patients with Locally Advanced or Metastatic Urothelial Cancer
10 Oct 2017 AnaptysBio Reports Positive Topline Proof-of-Concept Data from Phase 2a Clinical Trial of ANB020 in Atopic Dermatitis
10 Oct 2017 FDA Accepts Supplemental Biologics License Application For Prolia® (Denosumab) In Glucocorticoid-Induced Osteoporosis
09 Oct 2017 Mycenax Biotech Inc. announces TGA approval of phase I clinical trial authorization application for LusiNEX to treat autoimmune diseases
09 Oct 2017 The European Medicines Agency accepts marketing authorisation application for Imfinzi in locally-advanced unresectable non-small cell lung cancer
05 Oct 2017 eFFECTOR Therapeutics Initiates Dosing in Phase 2 Combination Trial of eFT508 and Avelumab in Microsatellite Stable Colorectal Cancer
05 Oct 2017 Chugai's Bispecific Antibody "ERY974" Results of Preclinical Study Published in Science Translational Medicine
03 Oct 2017 OSE Immunotherapeutics Presents New Data Strengthening the Rationale of Myeloid Checkpoint Inhibitor OSE-172 as an Immune Cancer Treatment
03 Oct 2017 Ablynx announces positive topline results from the phase III HERCULES study of caplacizumab for the treatment of acquired TTP
03 Oct 2017 Pieris Pharmaceuticals Announces Dosing of First Patient in Phase I Trial for Fully Proprietary Lead IO Program, PRS-343
03 Oct 2017 Seattle Genetics Receives FDA Breakthrough Therapy Designation for ADCETRIS® (Brentuximab Vedotin) in Frontline Advanced Hodgkin Lymphoma
30 Sep 2017 Siamab Therapeutics Presented New Data for its Anti-STn Antibody Therapeutics Showing Myeloid-Derived Suppressor Cells as a Promising Cancer Immunotherapy Target at Cambridge Healthtech Institute’s Targeting Tumor Myeloid Cells Conference
29 Sep 2017 Prothena Reports Results from Phase 1b Multiple Ascending Dose Study of PRX003 in Patients with Psoriasis
29 Sep 2017 FDA Grants Priority Review for Genentech’s Perjeta® (Pertuzumab) for Adjuvant Treatment of HER2-Positive Early Breast Cancer
28 Sep 2017 Immune Pharmaceuticals Announces Positive Results from Ongoing Phase 2 Trial of Bertilimumab in Bullous Pemphigoid
28 Sep 2017 AbbVie Announces Global Resolution of HUMIRA® (adalimumab) Patent Disputes with Amgen

La Merie Biologics

FREE Weekly News Bulletin

2016 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Top